We’re bringing the available data and research into view. Your report will appear here when it’s ready.
STOCK COMPARISON
Side-by-side fundamentals, valuation, and AI summaries for both tickers.
UNH
UnitedHealth Group Inc
UnitedHealth Group Inc has a market capitalization of $345.15B and a current stock price of $378.87, reflecting a daily decline of 2.42%. The company's P/E ratio stands at 28.64, with a revenue growth year-over-year of 11.81%, while EPS has decreased by 14.70% over the same period.
Investors may consider monitoring UnitedHealth's revenue trends and EPS performance as indicators of its financial health.
JNJ
Johnson & Johnson
Johnson & Johnson has a market capitalization of $645.20B and a current price of $265.58, reflecting a decrease of 0.29% from the previous close of $266.35. The company has a P/E ratio of 24.08 and an impressive EPS growth of 90.50% year-over-year, while revenue growth stands at 6.05%. The stock's 52-week high is $281.01, and the low is $173.47.
Investors should consider the company's financial metrics and market conditions when evaluating their positions.
| Metric | UNH | JNJ |
|---|---|---|
| Price | $378.87 | $265.58 |
| Market Cap | $345.15B | $645.20B |
| P/E Ratio | 28.64 | 24.08 |
| EPS Growth (YoY) | -14.7% | 90.5% |
| Revenue Growth (YoY) | 11.81% | 6.05% |
| ROE | 12.05% | 32.87% |
| Gross Margin | N/A | 67.88% |
| Net Margin | 2.69% | 28.46% |
| 52W High | $461.00 | $281.01 |
| 52W Low | $256.00 | $173.47 |
| Dividend Yield | 2.29% | N/A |
| Beta | N/A | N/A |
| D/E Ratio | 0.72 | 0.48 |
| Current Ratio | 0.79 | 1.03 |
UNH
Bull Case
Some investors highlight UnitedHealth's revenue growth of 11.81% year-over-year as a positive indicator of its operational strength. Additionally, the company's 52-week high of $461 suggests a potential for recovery.
Bear Case
Conversely, the 14.70% decrease in EPS year-over-year raises concerns about profitability. The recent stock price drop of 2.42% despite overall market gains suggests potential investor skepticism.
JNJ
Bull Case
Some investors cite Johnson & Johnson's robust EPS growth of 90.50% year-over-year as a strong indicator of its profitability and operational efficiency. Additionally, the company's focus on high-end MedTech growth areas may enhance its revenue potential moving forward.
Bear Case
Conversely, Johnson & Johnson's recent price decline of 0.29% may raise concerns about its short-term market performance relative to broader trends. The stock has also experienced a significant dip compared to its 52-week high of $281.01, suggesting potential volatility.
UnitedHealth Group Inc: UnitedHealth Group Inc has a market capitalization of $345.15B and a current stock price of $378.87, reflecting a daily decline of 2.42%. The company's P/E ratio stands at 28.64, with a revenue growth year-over-year of 11.81%, while EPS has decreased by 14.70% over the same period. Johnson & Johnson: Johnson & Johnson has a market capitalization of $645.20B and a current price of $265.58, reflecting a decrease of 0.29% from the previous close of $266.35. The company has a P/E ratio of 24.08 and an impressive EPS growth of 90.50% year-over-year, while revenue growth stands at 6.05%. The stock's 52-week high is $281.01, and the low is $173.47.
UnitedHealth Group Inc: Some investors highlight UnitedHealth's revenue growth of 11.81% year-over-year as a positive indicator of its operational strength. Additionally, the company's 52-week high of $461 suggests a potential for recovery. Johnson & Johnson: Some investors cite Johnson & Johnson's robust EPS growth of 90.50% year-over-year as a strong indicator of its profitability and operational efficiency. Additionally, the company's focus on high-end MedTech growth areas may enhance its revenue potential moving forward.
UnitedHealth Group Inc risks: Conversely, the 14.70% decrease in EPS year-over-year raises concerns about profitability. The recent stock price drop of 2.42% despite overall market gains suggests potential investor skepticism. Johnson & Johnson risks: Conversely, Johnson & Johnson's recent price decline of 0.29% may raise concerns about its short-term market performance relative to broader trends. The stock has also experienced a significant dip compared to its 52-week high of $281.01, suggesting potential volatility.
RESEARCH IS JUST THE BEGINNING
Bring your holdings into Helm for portfolio intelligence, daily briefs, and thesis monitoring. Start with one position.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions.